BRIEF-Anavex confirms data from Phase 2a study of ANAVEX 2-73 in Alzheimer's patients presented at AAIC 2016

* Anavex "remains dedicated" to advancing ANAVEX 2-73 and

will be reporting new data to investors as it becomes available

Read more